格列本脲与皮下胰岛素对妊娠期糖尿病围产期并发症的影响:一项随机临床试验
INDAO多中心非劣效性随机试验在法国13家大学医院纳入914名妊娠期糖尿病孕妇,比较口服格列本脲与皮下胰岛素对围产期并发症的预防效果。主要复合结局包括巨大儿、新生儿低血糖和高胆红素血症,格列本脲组发生率为27.6%,胰岛素组为23.4%,差异4.2%(单侧97.5%CI,-∞至10.5%;P=.19),未能证明格列本脲非劣效于胰岛素。
要点
- 格列本脲组主要围产期并发症发生率为27.6%,胰岛素组为23.4%,差异未达非劣效界值。
- 研究结果不支持将格列本脲作为妊娠期糖尿病的一线治疗。
- 该试验为多中心非劣效性设计,非劣效界值设为7%。
核心结论
- 在妊娠期糖尿病患者中,与皮下胰岛素相比,格列本脲未能证明不增加围产期并发症发生率。
- 这些发现不支持将格列本脲作为妊娠期糖尿病的一线治疗。
研究设计与样本
- 共纳入914名单胎妊娠且妊娠24至34周诊断为妊娠期糖尿病的孕妇,随机分配至格列本脲组(n=460)或胰岛素组(n=454)。
- 饮食干预10天后需要药物治疗的孕妇进入随机分组;格列本脲起始剂量2.5 mg口服每日一次,胰岛素起始剂量4 IU至20 IU皮下注射每日1至4次。
- 主要结局为巨大儿、新生儿低血糖和高胆红素血症的复合终点,非劣效界值设为7%(基于单侧97.5%置信区间)。
- 按方案分析纳入格列本脲组367名和胰岛素组442名孕妇及其新生儿;98%的随机参与者完成试验。
主要发现
- 格列本脲组主要结局发生率为27.6%,胰岛素组为23.4%,差异为4.2%(单侧97.5%CI,-∞至10.5%;P=.19)。
- 随机分组孕妇平均年龄32.8岁(SD,5.2岁)。
临床怎么用
- 对于妊娠期糖尿病需要药物治疗的孕妇,不应将格列本脲作为一线治疗选择。
- 临床决策时应优先考虑皮下胰岛素,而非口服格列本脲。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Randomized trials have not focused on neonatal complications of glyburide for women with gestational diabetes. OBJECTIVE: To compare oral glyburide vs subcutaneous insulin in prevention of perinatal complications in newborns of women with gestational diabetes. DESIGN, SETTINGS, AND PARTICIPANTS: The Insulin Daonil trial (INDAO), a multicenter noninferiority randomized trial conducted between May 2012 and November 2016 (end of participant follow-up) in 13 tertiary care university hospitals in France including 914 women with singleton pregnancies and gestational diabetes diagnosed between 24 and 34 weeks of gestation. INTERVENTIONS: Women who required pharmacologic treatment after 10 days of dietary intervention were randomly assigned to receive glyburide (n=460) or insulin (n=454). The starting dosage for glyburide was 2.5 mg orally once per day and could be increased if necessary 4 days later by 2.5 mg and thereafter by 5 mg every 4 days in 2 morning and evening doses, up to a maximum of 20 mg/d. The starting dosage for insulin was 4 IU to 20 IU given subcutaneously 1 to 4 times per day as necessary and increased according to self-measured blood glucose concentrations. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite criterion including macrosomia, neonatal hypoglycemia, and hyperbilirubinemia. The noninferiority margin was set at 7% based on a 1-sided 97.5% confidence interval. RESULTS: Among the 914 patients who were randomized (mean age, 32.8 [SD, 5.2] years), 98% completed the trial. In a per-protocol analysis, 367 and 442 women and their neonates were analyzed in the glyburide and insulin groups, respectively. The frequency of the primary outcome was 27.6% in the glyburide group and 23.4% in the insulin group, a difference of 4.2% (1-sided 97.5% CI, -∞ to 10.5%; P=.19). CONCLUSION AND RELEVANCE: This study of women with gestational diabetes failed to show that use of glyburide compared with subcutaneous insulin does not result in a greater frequency of perinatal complications. These findings do not justify the use of glyburide as a first-line treatment. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01731431.
引用
- Sénat MV, Affres H, Letourneau A, et al. Effect of Glyburide vs Subcutaneous Insulin on Perinatal Complications Among Women With Gestational Diabetes: A Randomized Clinical Trial. JAMA. 2018. PMID: 29715355. doi:10.1001/jama.2018.4072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。